First Command Bank raised its stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 0.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 883 shares of the medical research company’s stock after buying an additional 1 shares during the period. First Command Bank’s holdings in Thermo Fisher Scientific were worth $154,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in TMO. Trust Co increased its position in Thermo Fisher Scientific by 46.2% in the first quarter. Trust Co now owns 13,315 shares of the medical research company’s stock valued at $2,045,000 after buying an additional 4,209 shares during the period. Xact Kapitalforvaltning AB increased its position in Thermo Fisher Scientific by 1.1% in the second quarter. Xact Kapitalforvaltning AB now owns 79,765 shares of the medical research company’s stock valued at $13,917,000 after buying an additional 867 shares during the period. Catawba Capital Management VA increased its position in Thermo Fisher Scientific by 8.1% in the second quarter. Catawba Capital Management VA now owns 3,072 shares of the medical research company’s stock valued at $536,000 after buying an additional 230 shares during the period. Handelsbanken Fonder AB increased its position in Thermo Fisher Scientific by 17.3% in the second quarter. Handelsbanken Fonder AB now owns 118,465 shares of the medical research company’s stock valued at $20,669,000 after buying an additional 17,500 shares during the period. Finally, First American Trust FSB increased its position in Thermo Fisher Scientific by 52.1% in the second quarter. First American Trust FSB now owns 16,013 shares of the medical research company’s stock valued at $2,794,000 after buying an additional 5,482 shares during the period. Institutional investors and hedge funds own 83.52% of the company’s stock.

Shares of Thermo Fisher Scientific Inc (NYSE TMO) traded up 0.52% on Tuesday, reaching $179.35. 472,499 shares of the company were exchanged. Thermo Fisher Scientific Inc has a 12-month low of $139.07 and a 12-month high of $182.87. The firm has a market capitalization of $69.97 billion, a PE ratio of 31.25 and a beta of 1.06. The stock’s 50-day moving average is $176.80 and its 200 day moving average is $167.41.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.27 by $0.03. The business had revenue of $5 billion during the quarter, compared to analyst estimates of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period last year, the company earned $2.03 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc will post $9.24 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 15th will be paid a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 0.34%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s payout ratio is 10.45%.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.watchlistnews.com/first-command-bank-increases-position-in-thermo-fisher-scientific-inc-tmo/1529920.html.

Several equities analysts recently commented on the stock. Argus restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, August 22nd. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $197.00 price target on the stock in a research note on Tuesday, August 1st. BidaskClub downgraded shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Bank of America Corporation reaffirmed a “buy” rating and set a $210.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Friday, July 21st. Finally, Cleveland Research raised shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Thursday, July 20th. One investment analyst has rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $188.56.

In related news, Director Jim P. Manzi sold 11,318 shares of the firm’s stock in a transaction that occurred on Friday, August 18th. The stock was sold at an average price of $172.94, for a total transaction of $1,957,334.92. Following the completion of the sale, the director now directly owns 38,757 shares of the company’s stock, valued at approximately $6,702,635.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $172.79, for a total value of $3,455,800.00. Following the sale, the chief executive officer now directly owns 269,279 shares of the company’s stock, valued at $46,528,718.41. The disclosure for this sale can be found here. Insiders sold a total of 34,818 shares of company stock valued at $6,028,985 over the last ninety days. Corporate insiders own 0.49% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.